Targeting B7‐1 in immunotherapy

@article{Chen2019TargetingBI,
  title={Targeting B7‐1 in immunotherapy},
  author={Rui Chen and Aravindhan Ganesan and Isobel S Okoye and Elena Arutyunova and Shokrollah Elahi and M. Joanne Lemieux and Khaled H. Barakat},
  journal={Medicinal Research Reviews},
  year={2019},
  volume={40},
  pages={654 - 682}
}
Modulation of T‐cell immune functions by blocking key immune checkpoint protein interactions using monoclonal antibodies (mAbs) has been an innovative immunotherapeutic strategy. T‐cells are regulated by different checkpoint proteins at the immunological synapse including the B7 ligands (B7‐1 or CD80 and B7‐2 or CD86), which is discussed in this review. These ligands are typically expressed on antigen presenting cells and interact with CD28 and cytotoxic T lymphocyte antigen‐4 (CTLA‐4… 

New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials

TLDR
The biological behavior of various immune checkpoints has been proved in HCC, such as PD-1, programmed cell death ligand 1 (PD-L1), CTLA-4 and so on, leading to a series of clinical trials and the treatment of ICIs and various other therapies has been derived.

Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations

TLDR
This review discusses the cellular pathways related to T cell exhaustion, and the clinical development and possible cellular targets that can be exploited therapeutically to reverse this exhaustion.

Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis

TLDR
This article will highlight strategies designed to increase the immunogenicity of the breast tumor microenvironment and addresses the latest studies on targets which can enhance immune responses to breast cancer.

Beyond PD-L1—Identification of Further Potential Therapeutic Targets in Oral Cancer

TLDR
The upregulation of inhibitory receptors and ligands and the downregulation of activators could contribute to reduced effector T-cell function and could induce local immunosuppression in OSCC.

Selective Upregulation of CTLA-4 on CD8+ T Cells Restricted by HLA-B*35Px Renders them to an Exhausted Phenotype in HIV-1 infection

TLDR
The results aid to explain a novel mechanism for the inability of HIV-specific CD8+ T cells restricted by HLA-B*35Px to control viral replication and support the concept that CD8- T resistance to Tregs-mediated suppression is related to allele restriction rather than the epitope specificity.

CD80 expression is upregulated by TP53 activation in human cancer epithelial cells

TLDR
The pharmacological activation of TP53 can stimulate the expression of CD80 in human tumor cells of epithelial origin and provide the possibility that conventional TP53-activation approaches for tumoricidal effects may be repurposed for immunotherapy strategies.

VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment

TLDR
The present review focuses on the angiogenic and non-angiogenic functions of V EGF in NSCLC, especially the interaction between VEGF and the cellular components of the TME.

Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy

TLDR
This review describes literature reports on the application of peptide phage display to cancer immunotherapy and discusses three main outcomes of this procedure:phage display-derived peptides that mimic cancer antigens (mimotopes) and (ii) antigen-carrying phage particles, both as prophylactic and/or therapeutic vaccines, and (iii) phage displays as small-molecule effectors of immune cell functions.

A B7-CD28 Family-Based Signature Demonstrates Significantly Different Prognosis and Immunological Characteristics in Diffuse Gliomas

TLDR
This is the first mathematical model based on this gene family to provide novel insights into immunotherapy for diffuse glioma, and a B7-CD28 family-based nomogram was established to predict patient life expectancy contributing to facilitate personalizing therapy for tumor sufferers.

Molecular and Clinical Characterization of CD80 Expression via Large-Scale Analysis in Breast Cancer

TLDR
The findings suggest that CD80 might be a promising target for immunotherapeutic strategies after the first integrative study characterizing the role of the CD80 expression in breast cancer via large-scale analyses.

References

SHOWING 1-10 OF 240 REFERENCES

Understanding the CD28/CTLA‐4 (CD152) Pathway and Its Implications for Costimulatory Blockade

  • D. GardnerL. JefferyD. Sansom
  • Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2014
TLDR
An updated view of CTLA‐4 biology is provided, reviewing the established features of the system and highlighting its interplay with CD28, and how recent progress in understanding of this pathway affects the authors' interpretations following intervention is discussed.

The blockade of immune checkpoints in cancer immunotherapy

  • D. Pardoll
  • Biology, Medicine
    Nature Reviews Cancer
  • 2012
TLDR
Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.

The role of B7 costimulation in T‐cell immunity

TLDR
The present review outlines the current understanding of the physiological role of B7 costimulatory signals in regulating CD4+ T cell responses and identifies two major signalling pathways responsible for delivery.

At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy

TLDR
The unique mechanisms and sites of action of CTLA‐4 and PD‐1 suggest that although blockade of either has the potential to promote anti‐tumor immune responses, combined blockade of both might offer even more potent anti‐Tumor activity.

A more selective costimulatory blockade of the CD28‐B7 pathway

TLDR
The current understanding of this complex costimulatory pathway involving co‐stimulatory and co‐inhibitory molecules and the way the authors can manipulate these molecules to inhibit, stimulate or kill target cells is summarized in experimental preclinical models as well as in clinical trials.

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

TLDR
It is concluded that the combination of direct enhancement of Teff cell function and concomitant inhibition of T reg cell activity through blockade of CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti–CTLA- 4 antibodies during cancer immunotherapy.

Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets

  • H. TsaiP. Hsu
  • Biology, Medicine
    Journal of Biomedical Science
  • 2017
TLDR
Recent advance(s) in molecular understanding of T cell dysfunction in tumor microenvironments are reviewed and new immune checkpoint targets in cancer therapy are discussed.

Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population

TLDR
It is demonstrated here that CTLA-4 blockade can enhance or inhibit the clonal expansion of different T cells that respond to the same antigen, depending on both the T-cell activation state and the strength of theT-cell receptor signal delivered during T- cell stimulation.

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

TLDR
This review will focus on the endpoints of immune monitoring described in studies to date and discuss future areas of additional work needed, including ipilimumab and tremelimumab.
...